Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07142356 · ClinicalTrials.gov registry record · Phase 2

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

A Phase 2 study of Uncontrolled Hypertension, sponsored by Retension Pharmaceuticals..

Recruiting
Registry status
Phase 2
Development phase
280
Enrollment target
3
Study locations

NCT07142356 is a Phase 2 study of Uncontrolled Hypertension that is actively recruiting participants, run by Retension Pharmaceuticals.. The registered enrollment target is 280 participants, below the 736-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07142356, a Phase 2 study of Uncontrolled Hypertension, is actively recruiting participants, sponsored by Retension Pharmaceuticals..

RECRUITING
Registry status
Phase 2
Development phase
280 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are: Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? What medical problems do participants have when taking RTN-001? Researchers will compare RTN-001 to a placebo (a look-alike substance that contains no drug) to see if RTN-001 works to treat uncontrolled hypertension. Participants will: Take RTN-001 or a placebo every day for 12 weeks Visit the clinic about once every 2 weeks for checkups and tests Keep a diary of their symptoms and all medications that they take including RTN-001

Conditions Studied

Uncontrolled Hypertension

Interventions

  • DRUG RTN-001
  • DRUG Matching placebo control

Study Locations (3)

North Carolina

  • Retensiion Clinical Site - Monroe

South Carolina

  • Retension Clinical Site - Charleston

Virginia

  • Retension Clinical Site - Vienna

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2025-10-31
Est. Completion 2027-05
Phase Phase 2

Sponsor

Retension Pharmaceuticals.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07142356

The ClinicalTrials.gov registry entry for NCT07142356 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 736-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (62% lower). The listed sponsor is Retension Pharmaceuticals., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Uncontrolled Hypertension appearing as the primary indexed condition, and to 2 interventions - of which RTN-001 is the first listed.

NCT07142356 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, South Carolina, Virginia.

Frequently Asked Questions

What is clinical trial NCT07142356 about?

NCT07142356 is a clinical study titled "A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension". The goal of this clinical trial is to learn if the drug RT-001 works to reduce high blood pressure (hypertension) in adults. It will also learn about the safety of RTN-001. The main questions it aims to answer are: Does RTN-001 lower blood pressure in patients who have uncontrolled hypertension? Wh...

What is the current status of trial NCT07142356?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2025-10-31. Estimated completion is 2027-05.

What conditions does trial NCT07142356 study?

This clinical trial studies the following conditions: Uncontrolled Hypertension.

What interventions are being tested in trial NCT07142356?

The interventions under investigation include: RTN-001 (DRUG), Matching placebo control (DRUG).

Who is sponsoring clinical trial NCT07142356?

This trial is sponsored by Retension Pharmaceuticals., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07142356 being conducted?

This trial has 3 study locations across North Carolina, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uncontrolled Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uncontrolled Hypertension

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.